Literature DB >> 10775601

Successful vaccine-induced seroconversion by single-dose immunization in the presence of measles virus-specific maternal antibodies.

B Schlereth1, J K Rose, L Buonocore, V ter Meulen, S Niewiesk.   

Abstract

In humans, maternal antibodies inhibit successful immunization against measles, because they interfere with vaccine-induced seroconversion. We have investigated this problem using the cotton rat model (Sigmodon hispidus). As in humans, passively transferred antibodies inhibit the induction of measles virus (MV)-neutralizing antibodies and protection after immunization with MV. In contrast, a recombinant vesicular stomatitis virus (VSV) expressing the MV hemagglutinin (VSV-H) induces high titers of neutralizing antibodies to MV in the presence of MV-specific antibodies. The induction of neutralizing antibodies increased with increasing virus dose, and all doses gave good protection from subsequent challenge with MV. Induction of antibodies by VSV-H was observed in the presence of passively transferred human or cotton rat antibodies, which were used as the models of maternal antibodies. Because MV hemagglutinin is not a functional part of the VSV-H envelope, MV-specific antibodies only slightly inhibit VSV-H replication in vitro. This dissociation of function and antigenicity is probably key to the induction of a neutralizing antibody in the presence of a maternal antibody.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10775601      PMCID: PMC111985          DOI: 10.1128/jvi.74.10.4652-4657.2000

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  18 in total

1.  Measles antibody: reevaluation of protective titers.

Authors:  R T Chen; L E Markowitz; P Albrecht; J A Stewart; L M Mofenson; S R Preblud; W A Orenstein
Journal:  J Infect Dis       Date:  1990-11       Impact factor: 5.226

2.  Trial of high-dose Edmonston-Zagreb measles vaccine in the Gambia: antibody response and side-effects.

Authors:  H Whittle; P Hanlon; K O'Neill; L Hanlon; V Marsh; E Jupp; P Aaby
Journal:  Lancet       Date:  1988-10-08       Impact factor: 79.321

3.  Serologic status and measles attack rates among vaccinated and unvaccinated children in rural Senegal.

Authors:  B Samb; P Aaby; H C Whittle; A M Seck; S Rahman; J Bennett; L Markowitz; F Simondon
Journal:  Pediatr Infect Dis J       Date:  1995-03       Impact factor: 2.129

Review 4.  Increased mortality after high titer measles vaccines: too much of a good thing.

Authors:  N A Halsey
Journal:  Pediatr Infect Dis J       Date:  1993-06       Impact factor: 2.129

Review 5.  Measles vaccine: do we need new vaccines or new programs?

Authors:  S L Katz; B G Gellin
Journal:  Science       Date:  1994-09-02       Impact factor: 47.728

6.  Attenuated vesicular stomatitis viruses as vaccine vectors.

Authors:  A Roberts; L Buonocore; R Price; J Forman; J K Rose
Journal:  J Virol       Date:  1999-05       Impact factor: 5.103

7.  Transfer of measles, mumps, and rubella antibodies from mother to infant. Its effect on measles, mumps, and rubella immunization.

Authors:  H Sato; P Albrecht; D W Reynolds; S Stagno; F A Ennis
Journal:  Am J Dis Child       Date:  1979-12

8.  Measles virus replication in lungs of hispid cotton rats after intranasal inoculation.

Authors:  P R Wyde; M W Ambrose; T G Voss; H L Meyer; B E Gilbert
Journal:  Proc Soc Exp Biol Med       Date:  1992-10

9.  Measles, mumps and rubella immunization at nine months in a developing country.

Authors:  B D Schoub; S Johnson; J M McAnerney; L A Wagstaff; W Matsie; S G Reinach; D Vandevoorde; F E Andre; D E Teuwen
Journal:  Pediatr Infect Dis J       Date:  1990-04       Impact factor: 2.129

10.  Long-term survival after Edmonston-Zagreb measles vaccination in Guinea-Bissau: increased female mortality rate.

Authors:  P Aaby; K Knudsen; H Whittle; I M Lisse; J Thaarup; A Poulsen; M Sodemann; M Jakobsen; L Brink; U Gansted
Journal:  J Pediatr       Date:  1993-06       Impact factor: 4.406

View more
  42 in total

1.  A vesicular stomatitis virus recombinant expressing granulocyte-macrophage colony-stimulating factor induces enhanced T-cell responses and is highly attenuated for replication in animals.

Authors:  Elizabeth Ramsburg; Jean Publicover; Linda Buonocore; Amanda Poholek; Michael Robek; Amy Palin; John K Rose
Journal:  J Virol       Date:  2005-12       Impact factor: 5.103

2.  Insights into the regulatory mechanism controlling the inhibition of vaccine-induced seroconversion by maternal antibodies.

Authors:  Dhohyung Kim; Devra Huey; Michael Oglesbee; Stefan Niewiesk
Journal:  Blood       Date:  2011-02-28       Impact factor: 22.113

3.  Generation of hepatitis C virus-like particles by use of a recombinant vesicular stomatitis virus vector.

Authors:  Heather J Ezelle; Dubravka Markovic; Glen N Barber
Journal:  J Virol       Date:  2002-12       Impact factor: 5.103

4.  The hemagglutinin of canine distemper virus determines tropism and cytopathogenicity.

Authors:  V von Messling; G Zimmer; G Herrler; L Haas; R Cattaneo
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

Review 5.  Rhabdoviruses as vectors for vaccines and therapeutics.

Authors:  Gabrielle Scher; Matthias J Schnell
Journal:  Curr Opin Virol       Date:  2020-10-29       Impact factor: 7.090

6.  Lower levels of gamma interferon expressed by a pseudotyped single-cycle simian immunodeficiency virus enhance immunogenicity in rats.

Authors:  Yue Peng; Fan-ching Lin; Paulo H Verardi; Leslie A Jones; Tilahun D Yilma
Journal:  J Virol       Date:  2008-12-10       Impact factor: 5.103

7.  Replication-competent or attenuated, nonpropagating vesicular stomatitis viruses expressing respiratory syncytial virus (RSV) antigens protect mice against RSV challenge.

Authors:  J S Kahn; A Roberts; C Weibel; L Buonocore; J K Rose
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

8.  Protection against lethal vaccinia virus challenge by using an attenuated matrix protein mutant vesicular stomatitis virus vaccine vector expressing poxvirus antigens.

Authors:  Cassandra L Braxton; Shelby H Puckett; Steven B Mizel; Douglas S Lyles
Journal:  J Virol       Date:  2010-01-20       Impact factor: 5.103

9.  Refined methods for propagating vesicular stomatitis virus vectors that are defective for G protein expression.

Authors:  Susan E Witko; J Erik Johnson; Narender K Kalyan; Barbara K Felber; George N Pavlakis; Maninder K Sidhu; R Michael Hendry; Stephen A Udem; Christopher L Parks
Journal:  J Virol Methods       Date:  2009-11-24       Impact factor: 2.014

10.  A single immunization with a dry powder anthrax vaccine protects rabbits against lethal aerosol challenge.

Authors:  S D Klas; C R Petrie; S J Warwood; M S Williams; C L Olds; J P Stenz; A M Cheff; M Hinchcliffe; C Richardson; S Wimer
Journal:  Vaccine       Date:  2008-08-12       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.